Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Trial of Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Malignancies

NCT03095781 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT03095781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03095781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Trial of Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Malignancies
Lead sponsor
Emory University
Phase
Phase 1
Overall status
Completed
Start date
July 7, 2017
Completion date
June 10, 2021
Enrollment
47 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma, metastatic pancreatic adenocarcinoma, recurrent colorectal carcinoma, recurrent pancreatic carcinoma, stage iii colorectal cancer, stage iii pancreatic cancer, stage iiia colorectal cancer, stage iiib colorectal cancer, stage iv colorectal cancer, stage iv pancreatic cancer, stage iva colorectal cancer, stage iva pancreatic cancer, stage ivb colorectal cancer, stage ivb pancreatic cancer, unresectable pancreatic carcinoma